Last updated: February 24, 2026
What is NDC 65162-0802?
NDC 65162-0802 corresponds to Repatha (evolocumab), a monoclonal antibody used to lower LDL cholesterol levels. Approved by the FDA in August 2015, it is marketed primarily for hyperlipidemia and familial hypercholesterolemia. Repatha is administered via subcutaneous injection and targeted at patients unable to reach LDL cholesterol goals through statins alone.
Market Landscape
Competitive Position
- Main competitors include Praluent (alirocumab), Lomitapide, and Mipomersen.
- Repatha's advantage comes from its broader approval range, including heterozygous familial hypercholesterolemia and established cardiovascular risk reduction.
- As of 2022, Repatha held approximately 60% of the PCSK9 inhibitor market in the U.S. (IQVIA).
Market Size & Trends
- The global hypercholesterolemia treatment market was valued at $9.5 billion in 2021.
- Projected CAGR: 8.2% (2022-2027), driven by rising hyperlipidemia prevalence and new indications.
- U.S. prescriptions for PCSK9 inhibitors reached approximately 600,000 in 2022.
Pricing and Reimbursement
- Average wholesale price (AWP): Approximately $14,100 per year per patient.
- Net prices after discounts: Estimated at $8,000–$10,000 annually.
- Insurance coverage varies; prior authorization heavily influences access.
Patent and Regulatory Timeline
- Original patents expire in 2029.
- Multiple biosimilar efforts are ongoing but none approved yet.
- FDA approved expanded indications through 2023, including reduction in cardiovascular events.
Price Projections
Short-term (Next 1-2 Years)
- Anticipated price stability due to patent protection and limited biosimilar competition.
- Possible discounts for value-based pricing agreements may lower net costs by 10–20%.
- Insurance reimbursement rates expected to exert downward pressure.
Mid-term (Next 3-5 Years)
- Patent expiry around 2029 could result in biosimilar market entry.
- Biosimilars may reduce list prices by 15–30%, with potential net price decreases of 20–40% due to competition.
- Price reductions may accelerate if biosimilar approval occurs pre-expiry through legal or regulatory pathways.
Long-term (Post-2030)
- Complete biosimilar entry likely leads to significant price erosion.
- New formulations or indications could sustain higher prices if supported by clinical data.
- Market shifts for private payers pushing for lower prices.
| Period |
Expected Price Change |
Drivers |
| 2023-2024 |
Stable or slight decrease (~0-5%) |
Reimbursement negotiations, discounting |
| 2025-2026 |
Moderate decrease (~10-15%) |
Patent expiration near, biosimilar efforts |
| 2029+ |
Possible biosimilar entry; list price drops 15-30%; net prices 20-40% |
Biosimilar competition, market dynamics |
Key Market Risks
- Pending biosimilar approvals could lower prices.
- Regulatory changes or reimbursement policies may influence market value.
- Slow adoption or payer resistance could limit revenue growth.
- Development of alternatives targeting similar pathways.
Investment & Commercial Strategy
- Focus on patent extensions and new indications to prolong exclusivity.
- Engage with payers early for value-based pricing models.
- Prepare for biosimilar market entry by differentiating product offerings.
- Monitor clinical data that could justify premium pricing for new formulations.
Key Takeaways
- NDC 65162-0802, Repatha, dominates the PCSK9 inhibitor market in the U.S., with stable pricing until patent expiry.
- Current average annual net prices hover around $8,000–$10,000.
- Patent expiration around 2029 suggests potential for 20–40% market price reductions within five years.
- Biosimilar competition remains the primary risk, with regulatory and legal barriers delaying market entry.
- Long-term pricing hinges on biosimilar market penetration, new indications, and payer strategies.
FAQs
1. What factors influence Repatha's current pricing?
Repatha’s pricing is driven by manufacturing costs, clinical value, payer negotiations, and market competition. Reimbursement policies and discounting strategies also significantly affect net prices.
2. How will biosimilar competition impact Repatha’s market share?
Entry of biosimilars post-2029 is expected to reduce market share for the reference product, leading to price reductions and possibly increased adoption of biosimilars.
3. Are there emerging pipeline drugs that could replace Repatha?
New agents targeting PCSK9 pathways or alternative lipid-lowering mechanisms are in development, but none have achieved approval comparable to Repatha as of 2023.
4. What is the potential for Repatha to expand into new markets?
Expanded indications, such as prevention of recurrent cardiovascular events or use in broader patient populations, could increase the market size and sustain premiums.
5. How does Repatha’s pricing compare internationally?
Repatha’s list prices are generally higher in the U.S. than in Europe, where approval and reimbursement policies lead to lower net prices—often 30-50% less than U.S. prices.
References
[1] IQVIA. (2022). Market analysis and prescription data for PCSK9 inhibitors.
[2] FDA. (2015). Repatha (evolocumab) approval announcement.
[3] EvaluatePharma. (2022). Global hypercholesterolemia treatment market forecast.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for specialty drugs.
[5] U.S. Patent and Trademark Office. (2022). Patent expiration dates for PCSK9 inhibitors.
